Manifestations of malignant pleural effusions (MPEs) are alleviated by local therapies as well as by systemic treatment. After 2009, when commercial use of talc was discontinued in Korea, we have used Helixor-M, which is derived from the European mistletoe (Viscum album), as an alternative sclerosing agent for pleurodesis. We aimed to evaluate the efficacy and safety of Helixor-M for controlling MPE.
Between 2009 and 2015, we consecutively enrolled 52 patients with lung cancer, who underwent pleurodesis to treat MPE and were analyzed retrospectively. On day 1, 100 mg of Helixor-M was instilled via pleural catheter. If the procedure was not effective, it was repeated every other day up to five times, and the dose increased each time by 100 mg. The primary study outcome was reappearance of pleural effusion at 1 month after the last pleurodesis procedure.
The median age of patient was 63 years, and 77% of the 52 patients were male. About 85% of pleural effusions were found to be malignant by cytogenetic analysis. Forty-two (81%) patients were evaluable for recurrence of MPE. The 1-month recurrence rate was 48% (20/42). Among the 20 patients who developed recurrent MPE, 6 required therapeutic thoracentesis. Thirteen (25%) patients experienced procedure-related pain requiring medication. Eight (15%) had fever > 38 °C.
Our results suggest that a pleurodesis with Helixor-M was an effective and tolerable procedure for controlling MPE in lung cancer patients.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ, Group BTSPDG (2010) Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax 65(Suppl 2):ii32–ii40
Xia H, Wang XJ, Zhou Q, Shi HZ, Tong ZH (2014) Efficacy and safety of talc pleurodesis for malignant pleural effusion: a meta-analysis. PLoS One 9:e87060
Campos JR, Werebe EC, Vargas FS, Jatene FB, Light RW (1997) Respiratory failure due to insufflated talc. Lancet 349:251–252
Rehse DH, Aye RW, Florence MG (1999) Respiratory failure following talc pleurodesis. Am J Surg 177:437–440
de Campos JR, Vargas FS, de Campos Werebe E, Cardoso P, Teixeira LR, Jatene FB, Light RW (2001) Thoracoscopy talc poudrage : a 15-year experience. Chest 119:801–806
Mueller EA, Anderer FA (1990) A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon gamma inducer. Cancer Immunol Immunother 32:221–227
Bussing A, Regnery A, Schweizer K (1995) Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression. Cancer Lett 94:199–205
Evans M, Bryant S, Huntley AL, Feder G (2016) Cancer Patients' experiences of using mistletoe (Viscum album): a qualitative systematic review and synthesis. J Altern Complement Med 22:134–144
Stumpf C, Bussing A (1997) Stimulation of antitumour immunity by intrapleural instillation of a Viscum album L. extract. AntiCancer Drugs 8(Suppl 1):S23–S26
Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr (1972) Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 77:507–513
Kim JJ, Lee SK, Choi HH (2004) Viscum album therapy in malignant pleural effusion. Korean J Thorac Cardiovasc Surg 37:978–982
Cardillo G, Facciolo F, Carbone L, Regal M, Corzani F, Ricci A, Di Martino M, Martelli M (2002) Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions. Eur J Cardiothorac Surg 21:302–305 discussion 305-306
Steger V, Mika U, Toomes H, Walker T, Engel C, Kyriss T, Ziemer G, Friedel G (2007) Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses. Ann Thorac Surg 83:1940–1945
Yildirim H, Metintas M, Ak G, Metintas S, Erginel S (2008) Predictors of talc pleurodesis outcome in patients with malignant pleural effusions. Lung Cancer 62:139–144
Shaw P, Agarwal R (2004) Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002916.pub2
Janssen JP, Collier G, Astoul P, Tassi GF, Noppen M, Rodriguez-Panadero F, Loddenkemper R, Herth FJ, Gasparini S, Marquette CH, Becke B, Froudarakis ME, Driesen P, Bolliger CT, Tschopp JM (2007) Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 369:1535–1539
Martinez-Moragon E, Aparicio J, Rogado MC, Sanchis J, Sanchis F, Gil-Suay V (1997) Pleurodesis in malignant pleural effusions: a randomized study of tetracycline versus bleomycin. Eur Respir J 10:2380–2383
Davies HE, Lee YC (2013) Management of malignant pleural effusions: questions that need answers. Curr Opin Pulm Med 19:374–379
de Giorgio A, Stebbing J (2013) Mistletoe: for cancer or just for Christmas? Lancet Oncol 14:1264–1265
Conflict of interest
The authors declare that they have no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of Kangbuk Samsung Hospital Institutional Review Board (No. KBSMC 2016–07-045) and with the 1964 Declaration of Helsinki and its later amendments.
About this article
Cite this article
Lee, YG., Jung, I., Koo, DH. et al. Efficacy and safety of Viscum album extract (Helixor-M) to treat malignant pleural effusion in patients with lung cancer. Support Care Cancer 27, 1945–1949 (2019). https://doi.org/10.1007/s00520-018-4455-z
- Malignant pleural effusion
- Viscum album